Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 290 results for breast cancer

  1. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery

    Diagnostics guidance
    Published
    7 August 2013
    View recommendations

    Sections for DG8

  2. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at high risk Published...

  3. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published...

  4. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

    Network / system level indicators
    Last updated
    21 August 2024

  5. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately increased...

  6. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

    Technology appraisal guidance
    Published
    15 September 2021
    View recommendations

    Sections for TA725

  7. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased...

  9. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

    NICE guideline
    Published
    21 March 2024
    View recommendations

    Sections for NG241

  10. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

    Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA257

  11. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

    In development [GID-TA10919] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 September 2024.

    NICE guideline
    In consultation

  13. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development

  14. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    NICE is unable to make a recommendation on olaparib (Lynparza) for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy. This is because AstraZeneca did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    2 February 2022

    Sections for TA762

  15. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development